CURRICULUM VITAE



CURRICULUM VITAENAME: YIYAN LIU, MD, PhDHOME ADDRESS:132 Eastview Ave, Leonia, NJ 07605OFFICE ADDRESS:UMDNJ-University HospitalNuclear Medicine150 Bergen Street, H-140 Newark, NJ 071011. EDUCATION: 1987 - 1990Tongji Medical University Wuhan, ChinaPhDJuly 19901978 – 1983 Tongji Medical UniversityWuhan, ChinaMDJuly 19832. POST-DOCTORAL TRAINING:Internships and ResidenciesAlbert Einstein College of Medicine, Bronx, New YorkDepartment of Nuclear MedicinePET fellowship7/2003 – 6/2004 Albert Einstein College of Medicine, Bronx, New YorkDepartment of Nuclear MedicineResident 7/2001 – 06/2003 Sound Shore Medical Center, New Rochelle, New YorkDepartment of Surgery Internship7/2000 – 6/2001Union Hospital, Tongji Medical University, Wuhan, China Department of UrologyResident & Chief Resident7/1983 – 6/1989 Research FellowshipsUniversity of Maryland at Baltimore, Baltimore, Maryland Department of PhysiologyPostdoctoral Research Fellowship1/1993 – 6/20003. MILITARY: None4. LICENSURE: New York 230722exp. 11/30/14New Jersey 25MA07759500exp.6/30/135. CERTIFICATION:American Board of Nuclear Medicine2003 - 2023Certification Board of Nuclear Cardiology2005 - 2015Certified Clinical Densitometrist2009 - 20146. NATIONAL PROVIDER IDENTIFIER (NPI)12755583147. NARCOTICS CERTIFICATION:CDS D08566100 exp. 10/31/13DEABL8976485 exp. 3/31/168. UNIVERSITY APPOINTMENTS:Department of RadiologyUMDNJ-New Jersey Medical School, Newark, New JerseyAssociate Professor7/2010 – PresentDepartment of RadiologyUMDNJ-New Jersey Medical School, Newark, New JerseyAssistant Professor7/2004 – 06/2010 Department of SurgeryTongji Medical University, Wuhan, ChinaAssociate Professor7/1992 – 1/1993Department of SurgeryTongji Medical University, Wuhan, ChinaAssistant Professor7/1990 – 6/1992 9. HOSPITAL APPOINTMENTS:Department of RadiologyUMDNJ-University Hospital, Newark, New JerseyAttending physician7/2004 –Present Department of SurgeryTongji Medical University, Wuhan, ChinaAttending physician7/1990 – 1/199310. OTHER PROFESSIONAL POSITIONS AND MAJOR VISITING APPOINTMENTS:None11. AWARDS AND HONORS:Best Teacher of Residents Award 2012-2013BOARDS OF DIRECTORS / TRUSTEESNone13. MAJOR TEACHING EXPERIENCE:UMDNJ-New Jersey Medical School, Newark, New JerseyResident teaching including lectures and daily case interpretation7/2004 –PresentUMDNJ-New Jersey Medical School, Newark, New JerseyMedical student teaching (in summer rotations) 7/2004 –Present14. PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES:UMDNJ-University Hospital, Newark, New JerseyDepartment of RadiologyNuclear MedicineResponsibilities include: Nuclear medicine procedures and interpretation; PET-CT interpretation7/2004 -Present15. MAJOR COMMITTEE ASSIGNMENTSUMDNJMember, Institutional Review Board, Newark Campus, New Jersey2009 –Present16. MEMBERSHIPS, OFFICES AND COMMITTEE ASSIGNMENTS IN PROFESSIONAL SOCIETIES:The Society of Nuclear Medicine (SNM)Member2001 -PresentThe Radiological Society of North America (RSNA)Member2004 -Present17. MAJOR RESEARCH INTERESTS:I have a long term interest in prostate disease research from the basic science to the clinical aspects. I will continue to work on the molecular imaging of prostate cancer, specifically novel PET radiotracer for early diagnosis and detection of cancer recurrence. As a nuclear medicine specialist, I am also interested in the development of a new radionuclide therapy for prostate cancer. In addition, I have broad interests in PET imaging studies in various kinds of malignant tumors, for example the roles of PET in accurate staging and differential diagnosis between residual tumor and post-radiation necrosis for lung and cervical cancers.18. GRANT HISTORY:Society of Nuclear MedicineImaging of fatty acid oxidation in prostate cancer Pilot Research GrantFebruary 2005 – January 200719. MAJOR ADMINISTRATIVE RESPONSIBILITIES:None20. PRIVATE PRACTICE:None21. EDITORIAL MEMBER OF SCIENTIFIC JOURNALS:American Journal of Cancer Therapy and PharmacologyAmerican Journal of Cancer Case ReportsJournal of TumorWorld Journal of Methodology22. REVIEWER OF SCIENTIFIC JOURNALS:Journal of Nuclear MedicineClinical Nuclear MedicineNuclear Medicine and BiologyCancer LettersClinical EndocrinologyJournal of Molecular EndocrinologyLaboratory InvestigationJournal of Obstetrics and Gynecology ResearchClinical Genitourinary CancerReports in Medical ImagingJournal of Otology & RhinologyJournal of TumorWorld Journal of MethodologyWorld Journal of RadiologyWorld Journal of GastroenterologyJournal of Clinical Imaging ScienceOncoTargets and TherapyAmerican Journal of Cancer Therapy and PharmacologyAmerican Journal of Cancer Case ReportJournal of Neurology & NeurophysiologyJournal of Cancer Research and TherapeuticsJournal of Thoracic OncologyActa Obstetricia et Gynecologica ScandinavicaInternational Journal of Women’s HealthCurrent HIV ResearchInternational Journal of Stomatology and Occlusion MedicineClinicoEconomics and Outcome ResearchInternational Journal of Molecular Sciences23. BIBLIOGRAPHY:Liu Y, Franklin RB, Costello LC. Prolactin Specifically regulates citrate oxidation andm-aconitase of rat prostate epithelial cells. Metabolism 1996; 45:442-446.Liu Y, Franklin RB, Costello LC. Prolactin and testosterone regulation of mitochondrial Zinc in prostate epithelial cell. Prostate 1997; 30:26-31.Costello LC, Liu Y, Franklin RB. Zinc is a strong inhibitor of m-aconitase in prostate epithelial cells. Journal of Biological Chemistry 1997; 272:28875-28880.Costello LC, Liu Y, Franklin RB. Evidence for a zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone. Journal of Biological Chemistry 1999; 274: 17499-17503.Costello LC, Liu Y, Franklin RB. Testosterone stimulates the biosynthesis of m- aconitase and citrate oxidation in prostate. Molecular and Cellular Endocrinology 1995; 112:45-49.Costello LC, Liu Y, Franklin RB. Testosterone regulates pyruvate dehydrogenase E1 in prostate epithelial cells. Endocrine Journal 1994; 2:147-151.Costello LC, Y Liu and R Franklin. Prolactin specifically increases PDH-E1 in rat lateral prostate epithelial cells. Prostate 1995; 26:159-164.Costello LC, Liu Y, Franklin RB. Teststerone and prolactin stimulation of mitochondrial aconitase in pig prostate epithelial cells. Urology 1996; 48:654-659. Liang JY, Liu Y, Feanklin RB, Costello LC, Feng P. Inhibition of zinc on human prostate carcinoma cell growth. Prostate 1999; 40:200-205.Costello L, Liu Y, Franklin RB. Mitochondrial aconitase gene expression in regulated by testosterone and prolactin in prostate epithelial cells. Prostate 2000; 15:196-205.Costello LC, Liu Y, Franklin RB. Zinc causes a shift toward citrate at equilibrium of the m-aconitase reaction of prostate mitochondria. Journal of Inorganic Biochemistry 2000; 30:161-166.Costello LC, Liu Y, Franklin RB. The pyruvate dehydrogenase E1 alpha gene is testo-sterone and prolactin regulated in prostate epithelial cells. Endocrine Research 2000; 26:23-28. Liu Y, Park T, Chun KJ, Freeman LM. Uterine myoma identified on a Tc-99m MAG3 of a renal transplant. Clinical Nuclear Medicine 2002; 27: 801-802.Liu Y, Blaufox MD. Use of radionuclides to study renal function. In: Michael S. Goligorsky ( ed ). Renal Disease: Guide to technical approaches. The Humana Press Inc.: New Jersey, 2003. Page 79-117. Liu Y, Chun KJ, Freeman LM. “Shin through” on dual tracer parathyroid scintigraphy: a potential pitfall in interpretation. Clinical Nuclear Medicine 2005; 30: 145-149.Liu Y, Ghesani NV, Zuckier LS. Does timing of lasix administration affect ability to tolerate diuretic renography? Journal of Nuclear Medicine 2005; 46:1317-1320.Liu Y, Ghesani NV, Mirani N, Zuckier LS. PET-CT demonstration of extensive muscle metastasis from breast cancer. Clinical Nuclear Medicine 2006; 31: 266-268.Liu Y. Radiolabelled somatostatin analog therapy in prostate cancer: current status and future directions (review paper). Cancer Letter 2006; 239: 21-26. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer and Prostate Disease 2006; 9(3): 230-234.Bowers K, Liu Y, Ghesani N and Kim S. A level III sentinel lymph node in breast cancer. World Journal of Surgical Oncology 2006; 4: 31-34.Maldjian PD, Ghesani N, Ahmed S and Liu Y. Adenomyomatasis of the gallbladder: another cause for a “hot” gallbladder on F18-FDG PET. American Journal of Roentgenology 2007; 189:W36-W38.Liu Y. Metastatic brain lesions may demonstrate photopenia on FDG-PET. Clinical Nuclear Medicine 2008; 33:255-257.Liu Y. FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate. World Journal of Surgical Oncology 2008; 6:64-67.Liu Y. Bone marrow granulomatous inflammation: FDG-PET finding mimicking hematopoietic malignancy. Clinical Nuclear Medicine 2008; 33:707-708.Liu Y. Clinical significance of thyroid uptake on F18-fluorodeoxyglucose positron emission tomography (review paper). Annals of Nuclear Medicine 2009; 23:17-23. Liu Y. Benign ovarian and endometrial uptake on FDG-PET: patterns and pitfalls (review paper). Annals of Nuclear Medicine, 2009; 23:107-112.Liu Y. Nodal metastasis from occult thyroid cancer detected by FDG PET-CT in a patient with two known malignancies. Clinical Nuclear Medicine 2009; 34:371-373. Cohen EC, Baredes S, Zuckier LS, Mirani N, Liu Y and Ghesani N. F18-FDG PET evaluation of sinonasal papilloma. American Journal of Roentgenology 2009; 193:214-217.Liu Y. Clinical significance of diffusely increased splenic uptake on FDG PET-CT (review paper). Nuclear Medicine Communications 2009; 30:763-769.Liu Y. Setting a high SUV cutoff is misleading and meaningless in the differentiation of benign and malignant lesions of the head and neck ( Letter to Editor). Nuclear Medicine Communications 2009; 30:895.Liu Y. Benign orthopedic surgery related FDG uptake on PET-CT: case examples and pitfalls. Annals of Nuclear Medicine 2009; 23:701-708.Liu Y, Zuckier LS, Ghesani NV. Dominant uptake of fatty acid over glucose by prostate cells: a potential new diagnostic and therapeutic approach. Anticancer Research 2010; 30: 369-374.Liu Y, Ghesani NV, Zuckier LS. Physiology and pathophysiology of incidental findings detected on FDG-PET scintigraphy. Seminar of Nuclear Medicine 2010; 40: 294-315.Liu Y. Radionuclide imaging in prostate cancer. In Schwab M (ed): The Encyclopedia of Cancer, 3rd Edition. Heidelberg, Springer Science Publisher, 2011.Liu Y. Radionuclide therapy in prostate cancer. In Schwab M (ed): The Encyclopedia of Cancer, 3rd edition. Heidelberg, Springer Science Publisher, 2011.Liu Y. Metastatic female adnexal tumor of possible wolffian origin (FATWO) of the appendix demonstrated by FDG PET-CT: the first reported case. Clin Nucl Med 2011; 36:136-137.Liu Y. New therapeutic strategies in prostate cancer. In Holcroft R (ed). Treatment Strategies in Oncology. The Cambridge Research Center, London, 2010, on press (Epub ahead of print).Liu Y. Super-super scan on a bone scintigraphy. Clin Nucl Med 2011; 36: 227-228.Liu Y. Primary umbilical neoplasm demonstrated on FDG PET-CT. Clin Nucl Med 2011; 36: e-67-68.Liu Y. Characterization of thymic lesions with F18 FDG PET-CT: an emphasis of epithelial tumor. Nucl Med Communications 2011; 32: 554-562.Liu Y. Demonstrations of AIDS-associated malignancies and infections at FDG PET-CT. Ann Nucl Med 2011; 25: 536-546.Liu Y. Concurrent FDG avid nasopharyngeal lesion and generalized lymphadenopathy on PET-CT imaging is indicative of lymphoma in patients with HIV infection. AIDS Research and Treatment 2012 online; doi: 10.1155/2012/764291.Liu Y. Invalidity of SUV measurements of lesions in close proximity to hot sources due to “shine-through” effect on FDG PET-CT interpretation. Radiology Research and Practice 2012 online; doi: 10.1155/2012/867218.Liu Y. FDG PET-CT and renal scan demonstrations of carcinoma in the urinary bladder and bladder diverticulum. Clin Nucl Med 2013; 38:580-581.Liu Y. FDG PET differentiation of tumor recurrence from post-stereotactic radiosurgical scar in a central neurocytoma. Clin. Nucl Med 2013; 38:469-470. ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download